Welcome to INHIBRX
Inhibrx is a biotherapeutics company, founded in 2010, comprised of a unique team with a successful academic and industry track record. Inhibrx has an extensive internally developed pipeline focused on cancer and inflammatory diseases.
Inhibrx’s programs are based on comprehensive target discovery and selection expertise coupled to multiple proprietary antibody generation platforms to provide epitope diversity for all targets.
Inhibrx's oncology programs are further empowered through proprietary novel immune recruitment and activation technologies.
Inhibrx formed its first partnership with Celgene in 2012.